Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 13;129(5):782–790. doi: 10.1038/s41416-023-02344-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Springer Nature Limited 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

PMC Copyright notice

Fig. 1 — a Study design: patients were given pembrolizumab on day 1 of each cycle, and pelareorep on days 1, 2,3 and 8 of cycle 1 and days 1 and 8 of cycle 2 onwards. Blood and tissue biopsies were collected (as indicated) for molecular response analysis to treatment. b Swimmer plot of best responses of the 13 patients on the trial. c Progression Free Survival and d Overall Survival.